| 書目名稱 | Resistance to Immunotherapeutic Antibodies in Cancer |
| 副標(biāo)題 | Strategies to Overco |
| 編輯 | Benjamin Bonavida |
| 視頻video | http://file.papertrans.cn/829/828452/828452.mp4 |
| 概述 | Summarizes common and unique features of mAbs against various cancers.Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs.Covers the pot |
| 叢書名稱 | Resistance to Targeted Anti-Cancer Therapeutics |
| 圖書封面 |  |
| 描述 | ????The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance.?Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers?the common?and unique features of mAbs agains various cancer,?gives the latest developments on?the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance. |
| 出版日期 | Book 2013 |
| 關(guān)鍵詞 | Rituximab; antibody-drug conjugates; cancer drug resistance; mABs; monoclonal antibody; antibodies |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-1-4614-7654-2 |
| isbn_softcover | 978-1-4899-8732-7 |
| isbn_ebook | 978-1-4614-7654-2Series ISSN 2196-5501 Series E-ISSN 2196-551X |
| issn_series | 2196-5501 |
| copyright | Springer Science+Business Media New York 2013 |
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-12 18:21
發(fā)表于 2025-3-21 16:46:22
